[Emergency Pod] Peptides - Part 1 with Sunita Mohanty of Ultralight

Sunita Mohanty, CEO of Ultralight, describes how peptides have exploded onto the wellness radar, propelled by social media buzz and recent FDA signals that could move several top peptides out of the Category II list. That regulatory hint has already lifted the stock prices of companies like Hims & Hers and sparked a surge of interest among functional and integrative clinics. Ultralight’s AI‑native operating system now supports roughly 75 practices nationwide, helping them track peptide prescriptions, patient outcomes, and the ever‑shifting compliance landscape.

Despite the hype, clinicians confront a stark evidence gap; peer‑reviewed trials are scarce, so most practitioners lean on anecdotal results and the expertise of compounding pharmacies. Patients, eager for rapid relief, often self‑experiment, creating a black‑market ecosystem of unregulated Chinese suppliers and research‑grade peptides. Mohanty notes that adverse reactions can affect up to 30 % of users, underscoring the need for personalized dosing protocols and rigorous quality control. The prevailing advice for physicians is to partner with reputable compounding partners and stay current on FDA updates to mitigate safety risks.

The market dynamics are also gendered; early adopters are predominantly male body‑builders seeking muscle recovery, but women are rapidly entering the space as evidence expands into weight‑loss and anti‑aging applications. This broader adoption aligns with a growing policy push toward preventive health, where insurers could eventually reimburse peptide therapies if robust outcomes data emerge. For investors and health‑tech founders, the opportunity lies in building data‑rich platforms—like Ultralight’s AI system—that standardize outcomes, streamline pharmacy logistics, and de‑risk regulatory compliance, positioning peptides as a mainstream component of future preventive care.